AstraZeneca Offloads Two Mature CV Drugs For $500m
This article was originally published in PharmAsia News
Executive Summary
China Medical System has agreed to pay a total of $500m for selected rights to two mature AstraZeneca cardiovascular products, with the divestments set to provide new growth prospects for the Chinese firm while helping the UK-based multinational focus on innovative products in its second-largest global market.
You may also be interested in...
AstraZeneca’s Business Development Head Grady Outlines Strategy Mix
AstraZeneca’s total focus on its core therapy areas will ensure it keeps building external collaborations and doing deals to generate new therapies while maximizing revenues, but outright sales of non-core mature medicines are likely to be fewer going forward, according to the company’s head of business development.
China's Largest Pharma Promoter CMS Outpaced Market With Unique Specialty Pharma Focus
SHANGHAI - China Medical System Holdings, the largest third-party promotion service company in China, differs from its competitors by targeting small- and mid-size specialty pharma as clients, giving the company more secure contracts, higher profile products and bigger margins
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.